TY - JOUR
T1 - Adoptive cell-mediated immunotherapy with interleukin-2 (IL-2) for relapsing lymphoblastic crisis following mismatched unrelated bone marrow transplantation in a chronic myelogenous leukemia patient
AU - Varadi, G.
AU - Ackerstein, A.
AU - Ben-Neriah, S.
AU - Nagler, A.
PY - 1998/1/1
Y1 - 1998/1/1
N2 - A 21-year-old woman with chronic myelogenous leukemia (CML) relapsed into lymphoblastic crisis with new chromosomal translocations, 4 months following mismatched unrelated allogeneic bone marrow transplantation (BMT). Adoptive cell-mediated immunotherapy with mismatched unrelated donor lymphocytes followed by 3 days of in vivo interleukin-2 (IL-2) resulted in complete remission including disappearance of the Philadelphia chromosome as determined by cytogenetic analysis and the bcr/abl translocation detected by PCR. Lymphoblastic crisis following mismatched, unrelated BMT is relatively rare. Moreover lymphoblastic malignancies usually respond less favorably to cell-mediated immunotherapy. This case is the first reported CML lymphoblastic crisis following mismatched unrelated BMT that responded to cell-mediated immunotherapy and IL-2. Some possible mechanisms and new therapeutic directions are discussed.
AB - A 21-year-old woman with chronic myelogenous leukemia (CML) relapsed into lymphoblastic crisis with new chromosomal translocations, 4 months following mismatched unrelated allogeneic bone marrow transplantation (BMT). Adoptive cell-mediated immunotherapy with mismatched unrelated donor lymphocytes followed by 3 days of in vivo interleukin-2 (IL-2) resulted in complete remission including disappearance of the Philadelphia chromosome as determined by cytogenetic analysis and the bcr/abl translocation detected by PCR. Lymphoblastic crisis following mismatched, unrelated BMT is relatively rare. Moreover lymphoblastic malignancies usually respond less favorably to cell-mediated immunotherapy. This case is the first reported CML lymphoblastic crisis following mismatched unrelated BMT that responded to cell-mediated immunotherapy and IL-2. Some possible mechanisms and new therapeutic directions are discussed.
KW - Allogeneic unrelated BMT
KW - CML blastic crisis relapse
KW - Donor leukocyte transfusion
KW - Interleukin-2
UR - http://www.scopus.com/inward/record.url?scp=0031961848&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1701040
DO - 10.1038/sj.bmt.1701040
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 9486502
AN - SCOPUS:0031961848
SN - 0268-3369
VL - 21
SP - 93
EP - 96
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 1
ER -